Zurich, Switzerland

Isabel Patrizia Kerschgens

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Deutsches Krebsforschungszentrum. Active years: 2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Isabel Patrizia Kerschgens. Retrieved from https://idiyas.com/inventor/isabel-patrizia-kerschgens

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 17.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Isabel Patrizia Kerschgens: Innovator in Immune Activation

Introduction

Isabel Patrizia Kerschgens is a prominent inventor based in Zurich, Switzerland. She has made significant contributions to the field of immune activation through her innovative research and development.

Latest Patents

Isabel holds a patent titled "Substituted Aminoquinolones as DGKalpha Inhibitors for Immune Activation." This patent represents her groundbreaking work in the area of immune modulation, showcasing her expertise and dedication to advancing medical science. She has 1 patent to her name.

Career Highlights

Isabel is affiliated with the Deutsches Krebsforschungszentrum, a leading cancer research center. Her work there focuses on developing novel therapeutic strategies to enhance immune responses, which is crucial for cancer treatment and other immune-related conditions.

Collaborations

Isabel collaborates with talented colleagues, including Lars Wortmann and Thi Thanh Uyen Nguyen. These partnerships enhance her research efforts and contribute to the advancement of knowledge in her field.

Conclusion

Isabel Patrizia Kerschgens is a dedicated inventor whose work in immune activation is paving the way for future innovations in medical science. Her contributions are vital to understanding and improving immune responses, which can lead to better therapeutic options for patients.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…